A Retrospective, Molecular Study of EGFR and ALK Mutations in Non small cell Lung Cancer Patients

2016-08-01T18-40-25Z
Source: National Journal of Medical Research
Rakesh Taran, Deepak Singla, Prashant Kumbhaj, Prakash Chitalkar, vishesh Gumdal.
Background Epidermal growth factor receptor EGFR/ALK mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) and ALK inhibitor respectively,but knowledge of the EGFR/ALK mutation frequency on lung adenocarcinoma is still limited. Materials & Methods Our study is a retrospective study of the metastatic non small cell lung cancer patients harboring EGFR/ALK receptors.A total of 94 metastatic non small cell lung carcinoma patients data were evaluated,out of which 74 patients EGFR&ALK mutation status was known. Results All of the patients data evaluated in this study were in the age group of 30-74.Total 74 patients EGFR &ALK mutation status was known,out of which 34.2% were positive for EGFR and 4% for ALK respectively.In EGFR positive group 62.96%were male and 37.04% were female.Among males patients 34% were positive for EGFR as compared to 42% of EGFR Positive female patients. Conclusion Efforts to obtain tissue samples should be encouraged for EGFR&ALK mutation testing in non small cell lung carcinoma patients to provide a molecular basis to treat patients with available targeted therapy.


from Scope via xlomafota13 on Inoreader http://ift.tt/2avq8N7
via IFTTT